The depression screening market is expected to reach USD 657.82 Million by 2030 at 6.10%CAGR during the forecast period 2022-2030. The increasing problem of mental disorders all over the world and owing to the increase in the use of digital health technologies for mental health acts as s driving force for the growth of the depression screening market. The changing lifestyle and living standards and the growing use of smoking and the increase in the consumption of alcohol are the main factors that lead to the problem of mental disorder and hence leads to depression. Because of the growing population, and lack of medical experts the depression screening market is touching heights in terms of growth.
Depression is a common disease and it should not be mixed with regular sadness. It is a very dangerous disease as it affects the behaviour of a person. Hence depression test is required and in the technology-driven era, depression screening is done using advanced technology. The depression screening market is expected to grow at a high CAGR of 5.96% to reach USD 7836.67 million during the forecast period.
COVID 19 Analysis
The global pandemic of COVID 19 has not only affected the physical well-being of individuals, but it affected the psychological aspects also. Prolonged physical distance associated with social isolation, collective grief, the virus itself are some of the major side effects of COVID 19 which everyone has to face and it has put a negative impact on the minds of the people. Because of COVID 19, unemployment has also increased many times which not only affects the financial position but also affects emotionally. These are the few reasons which lead to mental disorders and hence depression.
Owing to the increase in the number of patients, it became necessary for the adoption of an online depression screening test. those who do not feel comfortable visiting doctors can use it from their place only and hence it is expected that the depression screening market will grow in the global market at the beginning of the second quarter of the coming year.
Owing the increase in the cases of mental disorders and the rise in the adoption of new therapies and treatments using advanced technology are the common factors that drive the growth of the depression screening market. Also, the World Health Organization has called depression the leading cause of disability across the globe it also drives the growth-share.
The increasing awareness among the people regarding the health issues and its timely screening have boosted the growth of the market. Also, the advancement in technology and its integration with the healthcare sector have helped in the growth of the global market. Because of the frequent suicide cases owing to the global pandemic many governments have taken initiatives regarding regular screening of depression or anxiety tests which is also a big opportunity for the depression screening market.
Although technology is booming in every sector possible still there is lack of awareness of mental disorders and treatments in most of the developing nations hinders the growth of the depression screening market.
Value Chain Analysis
Just like due importance is given to high blood pressure, diabetes, and various other physical disorders, the mental disorder should also be given due importance. That is why the depression screening market is growing at a high rate and screening is just the first step in getting help. Depression is not only a mental sickness but is an issue of major concern as it leads to suicidal tendencies.
With the depression screening market, now one can take free screening so that those who are in doubt regarding the symptoms of depression can get properly evaluated and can get treatment at an early stage.
The depression screening market has been divided based on division type, diagnosis, treatment, end-users, and region.
Based on disease type
The depression screening market is divided based on disease type into mood disorders, depression, bipolar disorders, anxiety, psychotic disorders, and eating disorders.
Based on diagnosis
The depression screening market is divided based on diagnosis into psychological tests, lab tests, and depression screening tests.
Based on treatment
The depression screening market is divided based on treatment into medication, brain-stimulation treatments, and substance abuse treatment.
Based on end-users
The depression screening market is divided based on end-users into hospitals and clinics, medical research centers, and academic institutes.
Based on region
The depression screening market is divided based on region into America, Europe, Asia-Pacific, and the Middle East, and Africa.
In the depression screening market, America holds the largest share. Out of which, owing to the availability of advanced diagnostic and treatment methods, an increasing number of patients, and raising funds for research, the North American region dominates the market.
The second-largest market share in the global depression screening method is held by Europe because of the development of healthcare facilities in many countries like Germany, France, and the U.K.
Owing to the fastest-growing region in the global market, Asia-Pacific holds the third position in the global market. Increasing development in countries like India, South Korea, and China in healthcare facilities has increased the demand for the depression screening market.
The major key players in the depression screening market are as follows:
Most of the major key players in the depression screening market in the global market operate using the key strategies of product development, innovation, and acquisitions, and mergers.
This depression screening market research report consists of the following:
This report contains various aspects related to the depression screening market along with future estimation, the impact of COVID 19 in increasing depression cases, and opportunities and challenges that the market face.
Data collection is done using large sample size and various statistical models are used to analyze the market data along with key trend analysis. DBMR research methodology is used in data triangulation that has an analysis of the impact of data variables in the market, data mining, and primary (industry expert) validation. Various primary respondents have been chosen for the sample size like doctors, surgeons, medical players, scientists, promotors, healthcare authorities, insurers, and others.
Pharmaceutical companies, the medical device industry, research, and development organization, academic institutes, diagnostic laboratories, healthcare payers, government institutes, and others.
|Market Size||USD 657.82 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Division type, Diagnosis, Treatment, End-users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (U.K.), Eli Lily and Company (U.S.), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson and Johnson Services, Inc. (U.S.)|
|Key Market Opportunities||
|Key Market Drivers||
Depression screening market projected to grow at approximately 5.96% CAGR during the assessment period (2020-2030).
The valuation of the depression screening market is estimated to increase to USD 657.82 Million by the end of 2030.
Increasing cases of patients with various mental disorders, changing lifestyle, and rising funding for R&D & clinical trials are major tailwinds pushing the growth of the global depression screening market.
North America holds the largest share in the global depression screening market, followed by Europe and the Asia Pacific, respectively.
ALLERGAN (Republic of Ireland), Alkermes (Republic of Ireland), AstraZeneca (UK), Eli Lilly and Company (US), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (US), and Otsuka Holdings Co., Ltd. (Japan), are some of the top players operating in the global depression screening market.